Core Insights - Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The company focuses on innovation-driven pharmaceutical development, targeting two core disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases [1] - Jingxin Pharmaceutical's business model combines the commercialization of existing products with the ongoing development of its product pipeline [1] Company Overview - Jingxin Pharmaceutical (002020.SZ) offers a diverse product portfolio that includes drugs (both generic and innovative), traditional Chinese medicine, biological agents, active pharmaceutical ingredients, and medical devices [1]

Group 1 - The core viewpoint of the article is that Zhejiang Jingxin Pharmaceutical Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1] - Jingxin Pharmaceutical is characterized as an innovation-driven pharmaceutical group focusing on two main disease areas: central nervous system diseases and cardiovascular and cerebrovascular diseases [1] - The company's business model combines the commercialization of already listed products with the continuous advancement of its product pipeline [1] Group 2 - The current product portfolio includes drugs (such as generic drugs, innovative drugs, traditional Chinese medicine, and biological agents), active pharmaceutical ingredients, and medical devices [1]

Group 1 - The core focus of Ascentage Pharma is on its research and development progress, particularly the initiation of Phase I clinical trials for its BTK degrader APG-3288 targeting relapsed/refractory hematologic malignancies, with a target enrollment of 360 patients [1] - The new drug clinical application (IND) for APG-3288 was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China on February 6, 2026, marking a new phase in the global multi-center clinical development of the drug [1] - APG-3288 utilizes the PROTAC technology platform aimed at overcoming resistance issues associated with traditional BTK inhibitors, providing a new treatment option for hematologic cancers [1] Group 2 - Ascentage Pharma's stock (06855.HK) experienced slight fluctuations over the past week, closing at 47.62 HKD on February 11, 2026, with a daily increase of 0.46% and a cumulative decline of 0.38% over the past five days [2] - The stock reached a peak price of 48.60 HKD on February 9 and a low of 45.74 HKD on February 10, with a trading range of 5.98% [2] - Southbound funds increased their holdings by 59,500 shares on February 10, with a net increase of 83,000 shares over the past five days, indicating short-term capital inflow [2]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. announced that its subsidiary, Suzhou Merdia Biopharmaceutical Co., Ltd., has received inclusion of its injectable SHR-A1811 (Rocatinib) in the list of breakthrough therapies by the National Medical Products Administration (NMPA), marking the 10th indication for which it has received breakthrough therapy certification [1] Group 1: Drug Information - Drug Name: Injectable Rocatinib (SHR-A1811) [1] - Acceptance Number: CXSL2000087 [1] - Drug Type: Therapeutic biological product [1] - Registration Category: Class 1 [1] - Application Date: December 2, 2025 [1] - Proposed Indication: First-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 (ERBB2) activating mutations [1] Group 2: Approved Indications - The injectable Rocatinib was approved for domestic market launch in May 2025, indicated for adult patients with unresectable locally advanced or metastatic NSCLC who have previously received at least one systemic therapy and have HER2 (ERBB2) activating mutations [2] Group 3: Market Context - Primary lung cancer is the most common malignant tumor globally, with GLOBOCAN 2022 data indicating approximately 2.48 million new cases and 1.82 million deaths annually, making it the leading cause of cancer mortality [3] - In 2022, China reported 1.06 million new lung cancer cases, accounting for 22.0% of all malignant tumors, and 733,300 deaths, representing 28.5% of all cancer deaths [3] - NSCLC accounts for about 85% of lung cancer cases, with approximately 2%-4% of NSCLC patients experiencing HER2 mutations, which are associated with high tumor invasiveness and poor prognosis [3] - Recent advancements in antibody-drug conjugates and highly selective HER2-TKIs have provided new treatment options for patients with advanced NSCLC harboring HER2 mutations [3] Group 4: Drug Mechanism and Competition - Injectable Rocatinib binds to HER2-expressing tumor cells, inducing cell cycle arrest and apoptosis through the release of toxins in the tumor cell lysosome [4] - Competing intravenous products in the domestic market include Roche's Ado-trastuzumab emtansine, AstraZeneca and Daiichi Sankyo's Fam-trastuzumab deruxtecan, Rongchang Biopharmaceutical's Vidisichu monoclonal antibody, and Kelun-Biotech's Bodo-trastuzumab [4] - According to EvaluatePharma, the global sales of similar products are projected to reach approximately $6.557 billion by 2024 [4] - Cumulative R&D investment for injectable Rocatinib is approximately 1.7725 billion yuan (unaudited) [4]

Group 1 - The company and its subsidiary, Hubei Tiensheng Pharmaceutical Co., Ltd., participated in the national organized procurement for drugs whose agreements have expired, and some products are proposed to be selected for this procurement [1] - If the procurement contracts are signed and implemented, it will help expand the sales range of the relevant products, increase market share, and enhance brand influence [1] Group 2 - The announcement was made on February 11, 2026, by the board of directors of Tiensheng Pharmaceutical Group Co., Ltd. [2]

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. has approved a capital reduction and corresponding amendments to its articles of association, following the repurchase and cancellation of 3,000 restricted stocks from its 2022 incentive plan [1][2]. Group 1: Company Actions - The company held its fourth board meeting on September 17, 2025, and a temporary shareholders' meeting on November 24, 2025, to discuss the capital reduction [1]. - The company has completed the registration change for its capital reduction and received a new business license from the Harbin New Area Management Committee [1]. Group 2: Company Information - The registered capital of Harbin Sanlian Pharmaceutical is now RMB 316,354,550 [1]. - The company was established on June 21, 1996, and operates in various sectors including drug production, wholesale, retail, and import/export, as well as cosmetics and food production [1][2]. - The company is classified as a joint-stock company and is publicly listed [1].

Group 1 - The company announced that its subsidiaries participated in a national centralized procurement process, with some products expected to be selected for procurement [1] - The procurement period for the selected products will last until December 31, 2028, and the company is unable to calculate the supply quantity at this time [1] - If the selected products are confirmed and contracts are signed, it will positively impact the company's sales, market share, and brand influence [2] Group 2 - The company approved a share repurchase plan on January 16, 2026, with a maximum repurchase price of 23.98 yuan per share and a minimum repurchase amount of 60 million yuan [6] - As of February 11, 2026, the company has repurchased a total of 6,856,400 shares, representing 0.65% of the total share capital, with a total expenditure of approximately 118.54 million yuan [7] - The repurchase will not significantly affect the company's operations, financial status, or future development, and the share distribution will still meet listing requirements [8]

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has participated in the continuation procurement of drugs whose agreements have expired under the national organization procurement program, with 13 products proposed for selection in this round [1][2]. Group 1: Proposed Selected Products - The proposed selected products include 12 that were previously selected in the first to eighth batches of the national organization procurement, and one new product, Paricalcitol Injection [2]. - The total expected sales revenue from these products is approximately 651.20 million yuan for 2024, accounting for 48.25% of the company's total revenue for that year [2]. - For the first nine months of 2025, the expected sales revenue is about 504.08 million yuan, representing 49.46% of the company's total revenue for that period [2]. Group 2: Impact on the Company - The procurement cycle for these selected products will run from the actual execution date of the selection results until December 31, 2028, with medical institutions prioritizing the use of these selected drugs [2]. - The overall procurement is expected to maintain price stability or further decline, providing medical institutions with greater choice and ensuring continuity in clinical medication [2]. - Although some selected products may see a decrease in price compared to previous sales, having 13 products proposed for selection allows the company to solidify its market share and enhance the accessibility of these drugs [2].

Financial Data and Key Metrics Changes - Total revenues for the full year 2025 were $216.1 million, a 9% increase compared to $198.8 million for 2024 [18] - Net product sales for Fanapt were $117.3 million, a 24% increase from $94.3 million in 2024 [18] - The company recorded a net loss of $220.5 million for 2025, compared to a net loss of $18.9 million in 2024 [21] - Operating expenses for 2025 were $367.3 million, up from $239.4 million in 2024 [24] Business Line Data and Key Metrics Changes - Fanapt's total prescriptions increased by 28% in 2025 compared to 2024 [19] - HETLIOZ net product sales were $71.4 million for 2025, a 7% decrease from $76.7 million in 2024 due to generic competition [20] - Ponvory net product sales were $27.4 million for 2025, a 2% decrease from $27.8 million in 2024 [21] Market Data and Key Metrics Changes - The total addressable market for the antipsychotic category is estimated at approximately $20 billion in 2025 [7] - The long-acting injectable antipsychotic market is projected to be in the $6 billion-$7 billion range for 2025 [12] Company Strategy and Development Direction - The company plans to initiate a dedicated phase III program for Nereus in the first half of 2026, targeting the GLP-1 agonist market [7] - Vanda aims to strengthen its psychiatric franchise with the anticipated approval of Bysanti for bipolar I disorder and schizophrenia [17] - The company is focused on expanding its commercial infrastructure and brand visibility through targeted sponsorships and marketing programs [26][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial launch of Nereus and the potential for significant market opportunities in motion sickness [6] - The company expects total revenues of $230 million-$260 million from current marketed products in 2026, indicating continued growth [40] - Management highlighted the importance of addressing unmet medical needs in major depressive disorder and social anxiety disorder through innovative therapies [10][12] Other Important Information - The company recorded a one-time, non-cash income tax charge of $113.7 million for the valuation allowance against deferred tax assets [22] - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $263.8 million, a decrease of $110.8 million compared to the previous year [26] Q&A Session Summary Question: Can you provide updates on Bysanti's FDA review and commercial strategy? - Management indicated optimism for an on-time approval and mentioned that commercialization would begin in Q3 2026 if approved [48] Question: What is the expected commercial infrastructure for Imsidolimab? - A small specialty sales force will be dedicated to marketing Imsidolimab, focusing on dermatologists and advocacy organizations [50] Question: Can you elaborate on promotional activities for Fanapt and Bysanti? - Current direct-to-consumer campaigns focus on Fanapt and Ponvory, with plans for a dedicated campaign for Bysanti upon its launch [52] Question: When will Nereus be commercially available? - Nereus is expected to be commercially available by late Q2 or early Q3 2026 [54] Question: What is the pricing strategy for Nereus? - While a specific price has not been communicated, it is expected to be at a premium compared to existing treatments for motion sickness [71]

张某与河南某药业公司分别向吉林某医药公司出具《承诺函》，就付款义务、违约责任、损失赔偿责 任、承担连带责任等作出承诺。 2024年，吉林某医药公司发现河南某药业公司和张某有挂网销售药品的行为，遂在多家电商平台回购了 发给河南某药业公司和张某的救心丸共计6531盒，并支付42.31万元。张某承认共窜货3000盒。 （来源：工人日报） 本报讯 （记者柳姗姗 彭冰 通讯员李雪）某公司签订了药品区域销售协议后，却将药品违约挂网销售、 擅自窜货。对于由此引发的高额违约金，法院将如何认定？近日，吉林省长春市绿园区人民法院审理了 这起合同纠纷案。 2023年1月，吉林某医药公司授权河南某药业公司、张某共同承包经营某救心丸在河南省区域的销售， 并签订协议约定代理商在承包期间不得超越代理范围，保证零售终端等下游客户不得有窜货、挂网销售 等不当行为，否则需支付惩罚性违约金。 河南某药业公司辩称，其与吉林某医药公司、张某之间实为挂靠关系，实际的药品销售方是吉林某医药 公司和张某。张某则表示，自己并没有将药品挂网销售、窜货，实际窜货人是其聘用的两位销售人员。 该案主审法官、长春市绿园区人民法院合心法庭庭长张季表示，依据相关法律法规， ...